Publications
Publications
  • October 2022
  • Case
  • HBS Case Collection

Cost Plus Drugs

By: Alexander MacKay and James Barnett
  • Format:Print
  • | Language:English
  • | Pages:12
ShareBar

Abstract

In September 2022, Mark Cuban Cost Plus Drugs Company CEO Alex Oshmyansky considered the future of the company. Cost Plus Drugs was a retailer for more than 340 generic oral medications, selling their drugs at significantly lower prices than typical pharmacies. Oshmyansky could focus resources on adding brand-name drugs to its medication portfolio or focus on the company’s ongoing development of a facility to manufacture sterile injectable drugs.

Keywords

Business Ventures; Decision Making; Entrepreneurship; Ethics; Health; Markets; Social Enterprise; Society; Strategy; Health Care and Treatment; Business Divisions; Factories, Labs, and Plants; Health Industry; Pharmaceutical Industry; United States; Texas

Citation

MacKay, Alexander, and James Barnett. "Cost Plus Drugs." Harvard Business School Case 723-362, October 2022.

About The Author

Alexander J. MacKay

Strategy
More Publications

More from the Authors